Palvella Therapeutics (PVLA) Non-Current Deffered Revenue (2016 - 2023)

Palvella Therapeutics (PVLA) has 8 years of Non-Current Deffered Revenue data on file, last reported at $759000.0 in Q2 2023.

• Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $759000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $759000.0 (changed N/A YoY) and the FY2022 annual result came in at $18.7 million, down 51.22% from the prior year.
• Non-Current Deffered Revenue fell to $759000.0 in Q2 2023 per PVLA's latest filing, from $11.7 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $59.7 million in Q1 2019 and bottomed at $759000.0 in Q2 2023.
• The 5-year median for Non-Current Deffered Revenue is $37.8 million (2020), against an average of $35.6 million.
• The widest annual swing landed in 2021, when Non-Current Deffered Revenue jumped 30.59%; it then plunged 61.95% in 2023.
• Tracing PVLA's Non-Current Deffered Revenue over 5 years: stood at $47.3 million in 2019, then dropped by 24.03% to $35.9 million in 2020, then gained by 6.97% to $38.4 million in 2021, then slumped by 51.22% to $18.7 million in 2022, then plunged by 95.95% to $759000.0 in 2023.
• Per Business Quant, the three latest PVLA Non-Current Deffered Revenue figures stand at $759000.0 (Q2 2023), $11.7 million (Q1 2023), and $18.7 million (Q4 2022).

Peer Comparison